Additionally, phosphodiesterase (PDE) inhibitors can increase intracellular cAMP levels by inhibiting cAMP hydrolysis, potentially regulating fat metabolism and improving obesity and diabetes-related metabolic disorders in animal experiments and some preclinical studies [25,26]. Here, ALDH7A1 is linked to metabolic disease.